Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent breast cancer.

Research Base: Alliance for Clinical Trials in Oncology
NCT ID: NCT01905046
NCI Protocol Number: A211102
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Metformin hydrochloride; Placebo

Condition

Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ

Trial Type

Cancer Prevention

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP